Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells

Introduction of tyrosine kinase inhibitors (TKIs) has improved the prognosis of patients with chronic myelogenous leukemia (CML), and treatment-free remission (TFR) is now a treatment goal. However, about half of the patients experience molecular relapse after cessation of TKIs, suggesting that leuk...

Full description

Saved in:
Bibliographic Details
Main Author: Maiko Matsushita
Format: article
Language:EN
Published: MDPI AG 2021
Subjects:
Online Access:https://doaj.org/article/d155489c7fbd45afb4e1e6b21cb70aad
Tags: Add Tag
No Tags, Be the first to tag this record!